ReproCell

ReproCell Revenue per Share

The Revenue per Share of ReproCell (4978.T) as of Oct 10, 2026 is 23.34 JPY. In the previous year, Revenue per Share was 31.46 JPY — a change of -25.79% (lower).

Revenue per Share

23.34JPY

YoY

-25.79%

Last updated:

Revenue per Share of ReproCell is 2026 23.34 JPY. Revenue per Share of ReproCell was 2025 31.46 JPY. It decreases by -25.79% lower compared to the previous year.

The ReproCell Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2020
16.80 JPY
Jan 1, 2021
16.57 JPY
Jan 1, 2022
26.31 JPY
Jan 1, 2023
34.72 JPY
Jan 1, 2024
25.75 JPY
Jan 1, 2025
31.46 JPY
Jan 1, 2026
23.34 JPY
Jan 1, 2027 (e)
38.02 JPY
The ReproCell Revenue per Share history
YEARRevenue per ShareYoY
est38.02JPY+62.85%
23.34JPY-25.79%
31.46JPY+22.14%
25.75JPY-25.81%
34.72JPY+31.93%
26.31JPY+58.80%
16.57JPY-1.35%
16.80JPY+10.19%
15.24JPY+16.96%
13.03JPY-33.77%
19.68JPY+7.65%
18.28JPY+84.96%
9.88JPY+11.80%
8.84JPY+2.00%
8.67JPY+162.01%
3.31JPY+13.81%
2.91JPY-51.14%
5.95JPY+13.06%
5.26JPY+142.79%
2.17JPY—
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Revenue per Share of ReproCell is 23.34 JPY in 2026.

Revenue per Share of ReproCell changed from 31.46 JPY to 23.34 JPY, representing a -25.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share ReproCell since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

Income Statement — ReproCell

All Key Metrics — ReproCell